RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca2+ assays. by Rebbeck, Robyn T et al.
UC Davis
UC Davis Previously Published Works
Title
RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening 
















eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRtS |         (2020) 10:1791  | https://doi.org/10.1038/s41598-020-58461-1
www.nature.com/scientificreports
RyR1-targeted drug discovery 
pipeline integrating FRET-based 
high-throughput screening and 
human myofiber dynamic Ca2+ 
assays
Robyn T. Rebbeck1,4, Daniel P. Singh2,4, Kevyn A. Janicek1, Donald M. Bers  3, 
David D. thomas  1, Bradley S. Launikonis  2* & Razvan L. cornea  1*
Elevated cytoplasmic [Ca2+] is characteristic in severe skeletal and cardiac myopathies, diabetes, and 
neurodegeneration, and partly results from increased Ca2+ leak from sarcoplasmic reticulum stores 
via dysregulated ryanodine receptor (RyR) channels. Consequently, RyR is recognized as a high-value 
target for drug discovery to treat such pathologies. Using a FRET-based high-throughput screening 
assay that we previously reported, we identified small-molecule compounds that modulate the skeletal 
muscle channel isoform (RyR1) interaction with calmodulin and FK506 binding protein 12.6. Two such 
compounds, chloroxine and myricetin, increase FRET and inhibit [3H]ryanodine binding to RyR1 at 
nanomolar Ca2+. Both compounds also decrease RyR1 Ca2+ leak in human skinned skeletal muscle 
fibers. Furthermore, we identified compound concentrations that reduced leak by > 50% but only 
slightly affected Ca2+ release in excitation-contraction coupling, which is essential for normal muscle 
contraction. This report demonstrates a pipeline that effectively filters small-molecule RyR1 modulators 
towards clinical relevance.
In striated muscle, contraction requires an intracellular Ca2+-release event mediated by ryanodine receptors 
(RyR) that are embedded in the sarcoplasmic reticulum (SR) membrane. Dysregulation of skeletal (RyR1) and 
cardiac (RyR2) isoforms, via mutations or excess posttranslational modification, has been linked to severe muscle 
pathologies, including malignant hyperthermia (MH), central core disease, muscular dystrophy (MD), sarco-
penia, catecholaminergic polymorphic ventricular tachycardia, heart failure, and more recently RyR2 has been 
recognized as a potentially significant contributor to diabetes and Alzheimer’s disease1–9. In most of these clinical 
indications, pathogenesis can be fueled by excess SR Ca2+ “leak” via RyR under resting cellular conditions, which 
leads to toxic intracellular basal [Ca2+] and insufficient SR Ca2+ load. As a result, RyR is intensely studied as a 
therapeutic target. Indeed, the therapeutic potential of pharmaceutically targeting RyR1-mediated SR Ca2+ leak 
in skeletal muscle has been shown in animal models of Duchenne MD, limb-girdle MD, and sarcopenia5,10,11. The 
therapeutic potential of targeting RyR2-mediated SR Ca2+ leak for treating heart failure and arrhythmia is also 
very well documented12–16. Additionally, targeting RyR2 (which is abundant in the brain17,18) may have therapeu-
tic potential for treating neurodegenerative diseases.
To introduce a systematic and efficient approach for identifying novel small-molecule chemical scaffolds with 
potential to mitigate RyR1 dysfunction, we developed and implemented a high-throughput screening (HTS) 
assay that uses fluorescence lifetime (FLT) detection of FRET19. This assay was designed to identify compounds 
that bind to the RyR1 channel complex to allosterically correct its pathologically leaky state (without affecting 
normal channel function)19. This FRET-based method is based on monitoring RyR binding of fluorescently labe-
led variants of two known RyR modulators–the FK506 binding protein (FKBP) 12.6 and calmodulin (CaM). 
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It has been shown that binding of CaM and FKBP to RyR can be allosterically influenced by small-molecule 
RyR modulators (e.g., dantrolene, K201, and S107) and RyR post-translational modifications9,20–23. Despite some 
controversy regarding the connection between RyR phosphorylation and FKBP association24,25, a growing con-
sensus is that CaM and/or FKBP binding to RyR may provide direct insight into the RyR structural state that has 
been associated with Ca2+ leak22,23,26–29. We previously used this HTS platform in a 384-well format to screen a 
small collection of compounds approved for clinical use19. In that report, we identified a correlation between the 
effects of Hit compounds on the FLT readout and RyR1 activity at resting Ca2+. Four Hits that reduced FRET 
also increased RyR1 activity, measured using [3H]ryanodine binding to skeletal heavy SR membranes (HSR)19. 
Correspondingly, the one Hit (chloroxine) that increased FRET also displayed the desired functional effect, 
which is RyR1 inhibition at resting [Ca2+]19. In a phenotypic screen by another group, using HEK293 cells stably 
expressing a genetically encoded ER Ca2+ sensor and an MH-linked RyR1 mutant, three compounds in common 
with Hits from our structural screen were identified as potential RyR1 modulators30. However, in that phenotypic 
screen, chloroxine’s effect on the readout suggested increased RyR1 activity, and thus was inconsistent with our 
findings19.
Here, our goals were to implement and validate our HTS assay in 1536-well plates (the industry standard), 
expand the array of potential RyR1 leak inhibitors, and directly correlate our FRET assay (structural) with Hit 
effects in an RyR1 leak assay (functional) that uses mechanically skinned human muscle fibers. This recently 
reported breakthrough technology preserves the excitation-contraction (EC) coupling apparatus31, which is 
essential for compound validation, given that current HTS methods lack the dihydropyridine receptor (DHPR), 
which is a crucial in vivo RyR modulator in the context of EC-coupling. Overall, we demonstrate a screening 
pipeline for RyR1-targeted drug discovery and development.
Results
HTS performance. To confer compatibility with current HTS standards in industrial drug discovery facil-
ities, we miniaturized our screening format from the previously established 384-well plates, requiring 50 μL 
sample per well19, to 1536-well plates, requiring 5 μL sample per well. The complete 1280-compound library of 
pharmacologically active compounds (LOPAC) was applied as 5 nL/well in 40 columns of one 1536-well black-
wall/black-bottom plate, with the remaining 8 columns loaded with 5 nL/well of DMSO, as no-drug controls. 
For each run of the screen, three plates were loaded with either (1) unlabeled HSR, or (2) HSR pre-incubated 
with donor-FKBP (D-FKBP; donor-only sample), or (3) donor-only sample that was additionally incubated 
with 0.3 μM acceptor-CaM (A-CaM) for 60 min prior to loading on the plate (donor-acceptor sample). This 
sub-saturating concentration of A-CaM was used to provide a readout that is sensitive to library compounds 
that may increase or decrease CaM binding affinity to RyR. To promote a homogenous population of RyR1 
resembling that associated with myopathies, final assay conditions also included 30 nM Ca2+ to represent rest-
ing (muscle relaxing) Ca2+, and 5 mM oxidized glutathione (GSSG), which exaggerates the conditions associ-
ated with oxidative stress32.
We acquired both FLT waveforms and fluorescence spectra, as previously described19,33,34. As previously 
observed19, Hit effects were greatest following a 2-hour incubation with the library compounds (Supplementary 
Fig. 1a). As a result, all FRET results shown in Figs. 1 and 2, and Supplementary Fig. 2 are reported from the 
2-hour incubation.
False Hits were filtered out when they altered the donor-only FLT by > 3 SD of the DMSO control mean, and 
also altered the integrated intensity of the unlabeled HSR spectrum by > 3 SD of the DMSO control.
From the collective of E/E0 values, we fit a narrow Gaussian distribution (σ = 0.016) centered over the control 
mean (μ = 1.004), which indicates that there is negligible bias to increase or decrease FRET (Supplementary 
Fig. 1b). The Zʹ value uses statistical effect size and signal variation as a gauge of HTS assay quality, with 
0.5 ≤ Z′ < 1 indicating an excellent assay that is ready for large-scale HTS35. Using 1536-well plates loaded with 
Figure 1. Reproducibility of the FLT-FRET HTS readout. RyR1-specific FRET (E) was measured in the 
presence of LOPAC compounds (10 μM test-compounds) in 1536-well format. Normalization was relative 
to DMSO-only controls (E0). Hits were those compounds that altered FRET by > 4 SD in at least two of three 
repeats of the screen. Each data point is shown as a solid black square, and means ± SE are shown in green, 
n = 3.
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10 μM suramin or DMSO (control), we found the Z′ values at the 20 min and 120 min reads were 0.83 ± 0.06 and 
0.88 ± 0.12, respectively. This excellent assay quality is very similar to our previous report using 384-well plates 
(Z′ = 0.89)19.
An initial Hit rate that is typically considered to be acceptable for an HTS assay ranges ~0.5–3%36. With appli-
cation of this guideline to our assay, we chose a threshold of four standard deviations (4 SD) of the controlDMSO 
mean, which led to 1.7–2.5% Hit rates in the three runs of the screen. Of the three screens, 22 compounds were 
Hits in at least two runs (Fig. 1), and 17 compounds were Hits in all three runs (Supplementary Table 1).
The LOPAC chemical collection contains previously established RyR modulators, and we were pleased that 
our screen identified some of these, including suramin, NF023, and disulfiram (Fig. 1)19,37,38. Furthermore, we 
also identified myricetin and temsirolimus, which are analogues of known RyR modulators quercetin and rapa-
mycin, respectively39,40. Indeed, suramin and rapamycin have been used as tools to induce dissociation of fluo-
rescently labeled CaM and FKBP12.0/12.6, respectively41,42. Additionally, cisplatin mediates CaM crosslinking 
at methionine residues43, which could explain the decrease in FRET. We were unsurprised to observe “frequent 
hitters” in screens and thiol modifiers, such as Reactive Blue44, SCH-20267645, cisplatin46, aurintricarboxylic 
acid47–49, and (6 R)-BH450. Several Hits that induce prominent FRET effects and/or are known functional mod-
ulators were further tested in dose-response FRET assays. Known RyR or CaM modulators for further testing 
included suramin, disulfiram, and cisplatin. We did not pursue further RyR assays with NF023, as this compound 
was previously established to be a less effective RyR modulator than its analogue, suramin37. Given that myricetin 
and temsirolimus are close analogues of known RyR modulators, we proceeded to further investigate whether 
these Hit compounds would regulate RyR activity or modulation via mechanisms dependent on FKBP or CaM in 
a similar manner as their analogue RyR modulators.
FRET dose-response assay. Necessary counter-screens to our pathological RyR1 conditions include evalu-
ating compound effects in healthy conditions and on the cardiac isoform, RyR2. Using the same FRET assay as in 
HTS, we tested the dose response of key Hits from this screen and the previously HTS-identified RyR1 inhibitor, 
chloroxine19, on healthy (5 mM GSH) and pathological (5 mM GSSG) conditions for both RyR1 in skeletal SR 
membranes, and RyR2 in cardiac SR membranes.
As previously observed, suramin abolishes FRET by 20 μM (Fig. 2a)41. Here, we note that suramin potency 
(IC50) was not altered by GSH or GSSG. However, we observe an isoform difference, with suramin’s RyR2 
Figure 2. FRET profiles for RyR1 and RyR2 over a range of Hit concentrations. The same FLT-detected FRET 
readout used in the primary HTS was measured at several Hit concentrations, using RyR1 and RyR2 samples. 
FRET dose-response of (a) suramin, (b) temsirolimus, (c) chloroxine, and (d) myricetin, measured at 30 nM 
Ca2+ using skeletal (green tones) and cardiac (red tones) SR membranes, in the presence of 5 mM GSSG 
(dark tones) or GSH (light tones). FRET efficiency in the presence of compound (E) was normalized to FRET 
efficiency in the presence of DMSO-only (E0). Data are presented as means ± SEM, n = 4. *P < 0.05 vs. DMSO 
by 2-sided Student’s unpaired T-test.
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potency slightly higher (IC50 was 2.5 ± 0.3 μM with GSH and 2.4 ± 0.6 μM with GSSG) compared to RyR1 (IC50 
was 5.9 ± 0.7 μM with GSH and 7.1 ± 0.5 μM with GSSG) (Fig. 2a). Screen Hit temsirolimus reduces FRET in a 
similar manner as other FKBP12.0/6 ligands, such as tacrolimus (Supplementary Fig. 2a) and rapamycin (a.k.a 
sirolimus)41. Notably, this FRET reduction by temsirolimus is subtle (~10%) for RyR1, but quite robust (68–70%) 
for RyR2 (Fig. 2b).
Chloroxine is the only RyR1 inhibitor we identified in a previous FRET-based screen of the 727-compound 
NIH Clinical Collection19. Consistent with this study, FRET was increased with micromolar chloroxine (Fig. 2c) 
for the RyR1 samples. However, chloroxine did not alter FRET with RyR2, indicating an RyR1-specific structural 
effect for this compound, and suggesting that chloroxine does not interact with RyR2 in a productive manner 
(Fig. 2c). Isoform specificity is highly desirable for potential therapeutics, and this result demonstrates that our 
screening assay can identify RyR isoform specific compound modulators.
We found a surprising result with myricetin, one of the LOPAC screen Hits that increases FRET (Fig. 1). Given 
that quercetin (a myricetin analogue) has been previously shown to increase RyR1 activity39, we were expect-
ing that myricetin would also be an activator, and therefore decrease FRET. We found the opposite – myricetin 
increased the FRET efficiency readout in the primary screens, and the FRET dose-response assays also show that 
myricetin increases FRET for RyR1 in the presence of GSSG or GSH (Fig. 2d). In contrast, FRET with RyR2 is 
strongly increased in the presence of GSSG, but strongly decreased in the presence of GSH (Fig. 2d), indicating 
again an intriguing isoform specificity.
FRET dose-response assays of select LOPAC Hits replicated the effect found in the primary screen. Similar to 
suramin, aurintricarboxylic acid abolished FRET at compound concentrations ≥ 10 μM (Supplementary Fig. 2b). 
Several compounds more strongly decreased FRET in the presence of GSSG vs. GSH. These compounds include, 
cisplatin (Supplementary Fig. 2c), disulfiram (Supplementary Fig. 2d), IPA-3 (Supplementary Fig. 2e) and SCH-
202676 (Supplementary Fig. 2g). In contrast, Ro 90–7501 has very similar FRET dose-response effects with GSSG 
or GSH. However, the Ro 90–7501 dose-responses are biphasic, whereby FRET is increased by sub-micromolar 
[compound], and decreased by micromolar [compound] (Supplementary Fig. 2f).
The Hit-induced effect on FRET between D-FKBP and A-CaM most likely results from one or the combination of 
factors, including a shift in CaM and/or FKBP12.6 binding, and/or structure of the RyR complex that shifts the D-A 
distance. Under the same assay conditions as in the primary screen, we assessed the effect of 10 μM Hit on fluorescent 
FKBP12.6 (F-FKBP) binding to RyRs, using co-sedimentation with pig skeletal and cardiac SR membranes. Overall, 
myricetin and suramin did not alter F-FKBP binding to RyR1 or RyR2, while temsirolimus and tacrolimus decreased 
F-FKBP binding to RyR1 and RyR2 by 20 and 70%, respectively (Supplementary Fig. 3). This suggests that myricetin- 
and suramin-induced FRET changes are due to shifts in CaM binding rather than shifts in FKBP binding, whereas 
temsirolimus induced FRET changes are due to shifts in FKBP (rather than CaM) binding, similar to tacrolimus.
Effect of hits on RyR activity using [3H]ryanodine assays. To evaluate the functional impact of com-
pounds identified through our FRET-based screen, we first used [3H]ryanodine binding assays. The level of [3H]
ryanodine binding to RyRs in SR membranes is a well-established index of the RyR channel activity51. Given the 
role of CaM binding in our FRET readout, we investigated whether CaM influences the functional effect of the 
Hit compounds by carrying out [3H]ryanodine binding assays in the absence and presence of CaM (300 nM).
In our previous study, we identified an inverse correlation between compound effects on FRET and RyR1 
activity, as measured by [3H]ryanodine binding. In particular, we identified chloroxine, a compound that 
increases FRET and decreases [3H]ryanodine binding to skeletal HSR by 20%19. When testing myricetin, shown 
to increase FRET within the skeletal SR samples here (Fig. 2d, RyR1), we observed a > 50% decrease in [3H]ryan-
odine binding by ≤ 10 μM myricetin, at 30 nM Ca2+, with or without CaM (Fig. 3a). However, 20 μM myricetin 
dramatically increased [3H]ryanodine binding, but only in the absence of CaM (Fig. 3a). This biphasic effect is 
more prominent at 30 μM Ca2+, with a maximum ~20% decrease in [3H]ryanodine binding reached at 1 μM 
myricetin, followed by an increase in [3H]ryanodine binding at higher myricetin concentrations. The biphasic 
Figure 3. [3 H]ryanodine binding profiles for RyR1 and RyR2 in the presence of a range of myricetin 
concentrations. Dose-dependent (0–20 μM) effect of LOPAC HTS Hit, myricetin, on [3 H]ryanodine binding 
to skeletal SR (a) and cardiac SR (b) in the absence of CaM (closed symbol) or in the presence of 300 nM CaM 
(open symbol), at 30 nM (blue) or 30 μM (red) free Ca2+. Data are shown normalized relative to the values for 
no-drug DMSO control (gray line), means ± SEM, n = 4–6. *P < 0.05 for no-CaM samples vs. DMSO control 
using 2-sided Student’s unpaired t-test; #P < 0.05 for 0.3 μM CaM samples vs. DMSO control using 2-sided 
Student’s unpaired t-test.
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effect elicited by myricetin in 30 μM Ca2+ is observed in both the presence and absence of 0.3 μM CaM (Fig. 3a), 
although the activation is more robust in the absence of CaM. In contrast to its RyR1 modulatory effects, micro-
molar myricetin only inhibits [3H]ryanodine binding to cardiac SR (RyR2), but this effect reaches significance 
only in the presence of CaM at 30 nM Ca2+ (Fig. 3b, left panel), and only in the absence of CaM at 30 μM Ca2+ 
(Fig. 3b, right panel).
To determine the functional effect of other FRET Hits, we also carried out [3H]ryanodine binding assays with 
ATA and Ro 90–7501. Similar to myricetin, the FRET enhancer Ro 90–7501 inhibited [3H]ryanodine binding 
(Supplementary Fig. 5). Conversely, the FRET inhibitor ATA is a potent inhibitor of [3H]ryanodine binding to 
skeletal SR (Supplementary Fig. 5). This is the first observed exception to the FRET-function correlation.
Assessing RyR modulators with human mechanically skinned fibers. By using SR membranes in 
[3H]ryanodine binding assays and FRET assays, we have explored the effects of myricetin and chloroxine on a 
relatively more purified, semi-physiological state of RyR1, in which the EC-coupling apparatus has been largely 
dismantled. To explore the functional effects of these RyR1 stabilizer compounds on SR Ca2+ leak in a physiolog-
ical system that has an intact EC-coupling apparatus, we used the recently established system of measuring SR 
Ca2+ leak via a confocal microscopy readout of enclosed transverse-tubule [Ca2+] in human and rat mechanically 
skinned skeletal muscle fibers31.
As schematically illustrated in Fig. 4a, at 200 nM cytoplasmic Ca2+ concentration ([Ca2+]cyto), RyR1 leaks 
Ca2+ into the junctional space (JS). The magnitude of the leak can be distinguished from the secondary source 
of Ca2+ to the JS, the Ca2+ diffusing in from the bulk cytoplasm, by comparing the steady-state [Ca2+] in the 
transverse-tubule system ([Ca2+]t-sys) in the presence and absence of RyR Ca2+ leak, with the use of a RyR blocker 
tetracaine31. The Ca2+ entering the JS sets the t-system steady-state level via the activity of PMCAs facing the 
JS, which is sensitive to nanomolar [Ca2+]31. The experimental model maintained [Ca2+]cyto at 200 nM. This is 
above resting physiological levels, thus overloading the SR and inducing an increase of RyR Ca2+ leak31. These 
conditions allowed the model to resemble that of a pathological nature. In a typical experiment, we use rhod-5N 
fluorescence to monitor [Ca2+]t-sys before and after bath exchange with one concentration of myricetin or chlorox-
ine (Fig. 4b). To determine the total [Ca2+]t-sys and the contribution of RyR1 leak to [Ca2+]t-sys, we exchange the 
bath solution with 30 mM caffeine and 1 mM tetracaine, respectively (Fig. 4b). Caffeine causes SR depletion and 
activation of store-operated Ca2+ entry (SOCE), which depletes [Ca2+]t-sys. As shown in Fig. 4b, recovery of the 
t-system fluorescence after washout of caffeine and re-introduction of standard solution after 10 μM myricetin or 
100 μM chloroxine, indicates that the modulators can be washed-out of the fiber.
As shown in Fig. 4c, the presence of 1 μM myricetin (P = 0.0027) and 10 μM myricetin (P < 0.0001) in bath 
solutions decreased the steady-state [Ca2+]t-sys compared to control (upper dotted line), indicating a decrease in 
RyR1 leak. However, given that the effect of 10 μM myricetin went beyond the effects of 1 mM tetracaine (lower 
dotted line), a known RyR channel blocker, we can infer that modulation of non-RyR targets leads to the addi-
tional decrease in t-system Ca2+. This suggests that high concentrations of myricetin inhibit RyR leak but also 
decrease the activity of the PMCA or open a Ca2+ efflux pathway from the t-system to lower [Ca2+]t-sys.
At all three concentrations tested, chloroxine progressively reduced the steady state towards that of 1 mM 
tetracaine (Fig. 4, lower dotted line). Only the presence of 100 μM chloroxine in internal solutions statistically 
decreased the steady-state [Ca2+]t-sys (P = 0.0002) (Fig. 4c).
The compound effects on mechanically skinned rat muscle fibers (Supplementary Fig. 6) were very compara-
ble with those observed on human skeletal muscle fibers (Fig. 4). Using the rat muscle fibers, we found that our 
compound solvent, DMSO, did not alter t-system fluorescence, indicating that 0.1% DMSO does not alter RyR1 
Ca2+ leak in our model system (Supplementary Fig. 6a).
Assessing RyR modulators with mechanically skinned fibers. To test the potential impact of these 
compounds on excitation contraction coupling, we measured voltage-induced Ca2+ transients in rat skeletal mus-
cle fibers. To do this, we again used mechanically skinned fibers. Because the t-system reseals upon mechanical 
skinning, bathing the preparation in a K+-based cytoplasmic solution (with a small amount of Na+) allows the 
Na+-K+ pump to re-establish the normal membrane potential. EC coupling can be initiated by exciting the prepa-
ration with field pulses that generate action potentials in the t-system to trigger Ca2+ release52–54. Ca2+ release is 
tracked by imaging rhod-2 in the cytoplasm via confocal microscopy in line-scan mode, and quantitatively plot-
ted in Fig. 5 (based on recordings such as shown in Supplementary Fig. 7). A major advantage of using skinned 
fibers is that known concentrations of RyR modulators can be added to the cytoplasm, as they were added in the 
“leak” experiments. With this approach, we found 1 and 10 μM myricetin reduced Ca2+ transient peak amplitude 
by 12% (P = 0.0046) and 48% (P < 0.0001), respectively (Fig. 5 and Supplementary Fig. 7a). In the case of chlorox-
ine, only addition of 100 μM led to a detectable 14% (P < 0.0001) reduction in the Ca2+ transient peak amplitude 
(Fig. 5 and Supplementary Fig. 7b). Therefore, both compounds, have impact on Ca2+ transients that is markedly 
lower than their effect on the t-tubule readout of RyR1 [Ca2+] leak (Figs. 4 and 5).
Discussion
We have used an FLT-FRET structural readout, of FKBP and CaM binding to RyR1, to identify small-molecule 
modulators of RyR1 channel function, with a particular interest in identifying compounds that mitigate patho-
logical RyR1 leak in low-nanomolar Ca2+ conditions that are typical of the resting muscle sarcoplasm. Through 
functional validation using [3H]ryanodine binding (an in vitro biochemical assay), we identified myricetin (this 
study) and chloroxine (preceding study)19 as RyR1 inhibitors. To validate the effectiveness of our RyR-specific 
FLT-FRET assay (a structural/binding readout) in identification of compounds that inhibit RyR1 channels in their 
natural context, we demonstrated the mitigating effects of these two compounds on RyR1 Ca2+ leak in mechani-
cally skinned human and rat skeletal muscle fibers.
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Assay metrics vs. previous screens. Relative to our previous screening format, we scaled up from 
384-well plates to 1536-well plates, which are typically used for large-scale primary screening in the HTS facili-
ties of pharmaceutical companies. This transition reduced the sample consumption by 10-fold (from 50 to 5 μL 
per well), and increased the data acquisition rate by 40% (from 6583 wells/hour to 9216 wells/hour) without 
degrading signal window or precision. Thus, the excellent quality of this HTS assay is preserved, as indicated by 
Figure 4. Effects of HTS Hits on t-tubule Ca2+ measurements of RyR1 leak in human skinned skeletal muscle 
fibers. (a) Diagram showing how rhod-5N trapped in the sealed t-system can be used to detect RyR Ca2+ leak. 
At rest, Ca2+ leaks through the RyR into the junctional space, where it is taken up by the NCX and PMCA, 
thus resulting in a net increase of [Ca2+]t-sys (left). Blockage of the RyR inhibits Ca2+ leak into the JS (right). 
The difference in [Ca2+]t-sys under these conditions represents total Ca2+ leak31. (b) Representative traces of 
t-tubule Ca2+ in response to RyR modulators. Solution exchanges are indicated by the blue, vertical bars. The 
blue horizontal line indicates the presence of 200 nM [Ca2+]cyto (standard solution) in the fiber bathing solution, 
which loads the SR and t-system with Ca2+ in the presence of functional RyRs. The functional RyR leaks 
Ca2+ into the junctional space to increase local [Ca2+] at the t-system and increase t-system Ca2+-dependent 
fluorescence. The addition of RyR modulators to the standard solution are indicated by the horizontal lines. 
Each RyR modulator causes a reduction in rhod-5N fluorescence, indicating an effect on RyR Ca2+-leak. The 
red horizontal line indicates the change to a bathing solution with 30 mM caffeine, which causes SR depletion 
and activation of SOCE to deplete the t-system of Ca2+. (c) dosage response curve was developed using 0.1, 1 
and 10 µM of myricetin (means ± SEM, *P < 0.05, n = 4) and 1, 10 and 100 µM of chloroxine (means ± SEM, 
*P < 0.05, n = 4–8). The “1 mM Tetracaine” dotted line indicates full RyR inhibition (mean, n = 11). The 
“Control [Ca2+] uptake” dotted line represents no-drug control (full t-system uptake) (mean, n = 15).
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the industry standard of HTS assay quality, a factor Z′ that is > 0.5. Currently, our throughput (1536- vs. 96-well 
plates) and HTS assay quality (as indicated by Z′ > 0.8 vs. < 0.5) exceeds all other published screening methods 
for identifying RyR modulators30. In particular, the approach reported by Murayama and colleagues30, of moni-
toring compound effects on ER Ca2+ in HEK293 cells, directly detects therapeutically desirable increases in ER 
Ca2+. However, their method does not discriminate between allosteric modulators and channel blockers, whereby 
channel blockers would be therapeutically undesirable. Neither assay platform (ours or Murayama’s) preserves 
the excitation-contraction coupling apparatus, which is a clear limitation of these platforms. This is why we uti-
lized structurally intact adult skeletal muscle fibers to validate the Hit effects on RyR1 channel leak in its native 
context, with intact DHPR interaction and all other membrane-bound components of the EC-coupling apparatus 
unperturbed.
FKBP and CaM binding as a readout of Hit interaction with the RyR channel complex. Our 
previous study indicated an inverse correlation between compound effects on FRET and [3H]ryanodine bind-
ing (more FRET correlated with less [3H]ryanodine binding and vice-versa)19. However, the limited number 
of reproducible Hits (5 compounds) in that screen was insufficient for understanding the mechanism that ties 
our FRET readout with the impact on RyR function. The number of promiscuous compounds in the LOPAC 
library was a favorable factor for discovering more compounds that interact with the RyR1 complex (Hits). As 
hoped, our LOPAC screen identified a greater number of reproducible Hits (Fig. 1), especially compounds that 
increase FRET (Fig. 1). Several Hits were known RyR modulators or their analogues, and modulated FRET in a 
fashion that largely reflects our previously identified inverse correlation between FRET and functional effect of 
compound19. Such compounds include suramin, NF023, temsirolimus and myricetin, with the last three com-
pounds being analogues of suramin, rapamycin and quercetin, respectively37,38,41,42. As anticipated for a rapamy-
cin analogue, temsirolimus, we found FRET reduced in a manner that correlates with reduced F-FKBP binding. 
Furthermore, temsirolimus more strongly reduced FRET and F-FKBP binding with RyR2 than to RyR1, which is 
reminiscent of a recent report that found disruption of FKBP12.0 binding by RyR modulator CLIC2 was stronger 
with RyR2 than RyR155.
As previously observed, suramin abolished FRET by promoting CaM dissociation, not FKBP dissociation41. 
Similarly, myricetin altered FRET, but did not alter F-FKBP binding (Supplementary Fig. 3), suggesting that 
the FRET increase is driven by myricetin mediating increased CaM binding to RyR1 and RyR2. Curiously, the 
functional effect of myricetin on RyR1 was observed in the presence and absence of CaM under nanomolar Ca2+, 
though the effect was subtly affected by the presence of CaM under micromolar Ca2+. Myricetin also inhibited 
RyR2 in nanomolar Ca2+ and this effect required CaM. This apparent allosteric interplay of myricetin and CaM 
binding to RyR is similar to that reported for dantrolene and CaM in binding to RyR2 in cardiomyocytes22,23,56.
In the case of several hits, the compound effect was very similar between GSSG and GSH conditions, with 
the exception of myricetin on RyR2 in cardiac SR membranes, whereby FRET was decreased and increased in 
GSSG and GSH conditions, respectively (Fig. 2d). This suggests that myricetin may also act on RyR2 by alter-
ing posttranslational modifications, which are known to affect the RyR2-CaM interaction22,23. In comparison, 
GSH and GSSG did not elicit significantly different myricetin effects with the RyR1 FRET readout (Fig. 2d). This 
implies important differences in the myricetin mechanism of action with RyR1 vs. RyR2, in the presence of GSH. 
Resolving the details of myricetin’s mechanism of action, and its functional impact on RyR2 in vivo, will be the 
focus of separate studies.
As observed in the NIH Clinical Collection screen19, it appears to hold true that compounds that increase 
FRET decrease RyR activity in GSSG conditions. However, we found the inverse does not necessarily hold true, as 
ATA substantially decreased both FRET and RyR1 activity.
Figure 5. Effect of micromolar myricetin and chloroxine on electrically evoked Ca2+ transients. In rat skinned 
fibers, Ca2+ transients were obtained by confocal line scans parallel to the fiber long axis, with corresponding 
line averaged and normalized rhod-2 fluorescence signals (F/F0). Representative recordings of Ca2+ transients 
are shown in Supplementary Fig. 7. All solutions contained 1 mM EGTA and 100 nM free Ca2+. Cytosolic Ca2+ 
transients were elicited by electrical field stimulation at 1 Hz in the presence of DMSO (control), myricetin or 
chloroxine. Dotted line represents 0.1% DMSO control (which causes no detectable reduction in EC-coupling). 
Data presented as means ± SEM, *P < 0.05, n = 6.
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Testing leak in human skeletal muscle fibers. Our results indicate that the inhibitory effect of chlorox-
ine19 and myricetin (Fig. 3) on RyR1 function in skeletal SR membranes can be replicated on RyR1 SR Ca2+ leak 
in human and rat skinned skeletal muscle fibers (Fig. 4, Supplementary Fig. 6). Curiously, the effect of 10 μM 
myricetin goes beyond the effects of tetracaine, which was used to zero the RyR1 contribution to SR Ca2+ leak. 
This is probably due to myricetin having secondary effects on t-tubule [Ca2+]. Notably, reversibility of compound 
effects suggest that this is not due to shifts in post-translational modifications (Fig. 4b), but rather to a direct effect 
on t-system Ca2+ uptake or release. The versatility of the mechanically skinned fiber preparation57 also allowed 
assessment of RyR1 modulators on action potential induced Ca2+ release, as previously demonstrated with dant-
rolene54. Optimally, the ideal RyR1 modulator must mitigate pathological leak but also have minimal effect on 
normal EC coupling within the muscle. Furthermore, the modulator should have minimal effects on healthy 
RyR2 isoforms, otherwise healthy cardiac and brain function may be adversely effected. Although not completely 
ideal, myricetin displays a lot of desirable modulatory effects, including reducing RyR1 activity and SR Ca2+ leak, 
while having minimal functional effects on RyR2 activity. Thus, myricetin may be a test candidate for treatment 
of skeletal muscle disease animal models, including MD and sarcopenia.
Overall, information provided by these skinned skeletal muscle fiber assays is important because it identi-
fied RyR Ca2+ leak inhibitors with potential for lead compound development, showed concentration dependent 
reductions in SR [Ca2+] leak, showed non-specific effects of modulators, and most importantly for clinical rele-
vance, showed the effects on EC coupling.
Strengths and limitations of the primary screening assay. We describe a target-focused primary 
HTS assay that uses a high-precision FLT-FRET readout that is specific to the RyR. Target identification is criti-
cally facilitated via binding of donor-labeled FKBP12.6 to its sole partner in sarcoplasmic reticulum – the RyR, 
and then observing FLT changes due to binding of acceptor-labeled CaM within FRET range of the donor. Thus, 
by looking under the donor lamp post we obtain a signal exclusively corresponding to A-CaM binding to RyR, 
as opposed to A-CaM binding to other targets in SR. This is essential to demonstrating RyR engagement at the 
earliest steps of the screening funnel (Fig. 6). Demonstration of target engagement represents a significant chal-
lenge in the case phenotypic HTS platforms, such as described by Murayama and colleagues30. A limitation of 
structure-based, target-focused HTS assays, such as ours, may be that functional validation of the Hits occurs in 
downstream studies that could be resource-intensive. To address this limitation, we use a structural readout of 
CaM-RyR binding that has been strongly correlated to functional effects19,22,23,26. As discussed above, this correla-
tion holds for most (but not all) Hits, meaning that the direction of FRET change is not a perfect predictor of the 
functional effect of a Hit. Compounds that bind to the target (RyR) and do not affect its properties in a manner 
that affects the structural readout will go undetected (false negatives). This is a typical limitation of target-based 
HTS assays in general, i.e., not all desirable effectors will be picked up. For an enormous target such as the largest 
known channels, the RyRs, one could hypothesize that some small-molecule modulators could bind without 
an effect on the FRET readout. This is especially if they bind to RyR structural elements situated between the 
FKBP or CaM binding site and the channel pore, and do not produce retrograde structural rearrangements that 
Figure 6. RyR1 Drug Discovery Pipeline. Green boxes denote early-stage steps (assays) in the RyR1 drug 
discovery pipeline that are covered in this report. In red, we summarize additional steps that will be necessary in 
a full-scale drug discovery campaign.
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affect FKBP or CaM binding or their distance relationships. We view this as a testable basic-science hypothesis. 
However, recent structural studies have revealed well-defined structural pathways for allostery connecting the 
outskirts of the RyR cytosolic cap to modulate the transmembrane pore opening58. Moreover, we feel that our 
readouts – RyR binding of CaM or FKBP – are well documented as linked to the RyR functional state, and their 
disrupted binding has been consistently observed in pathological states19–23,26,28,29,59,60.
In conclusion, we describe a pipeline for early-stage RyR1-targeted drug discovery by demonstrating that the 
FLT-FRET structural readout of our HTS-compatible platform can identify compounds that inhibit a biochemical 
index of RyR channel function (the [3H]ryanodine binding assay), as well as RyR1 leak in skinned human and rat 
skeletal muscle fibers. We also use muscle fibers to evaluate the effect of compounds on EC coupling, as evidenced 
by voltage-induced Ca2+ transients. The compounds identified by our FRET-based HTS assay and further tested 
on skeletal muscle fibers are unlikely to be considered potential therapeutics, but they can represent starting 
points for lead development with iterations of testing analogue compounds generated by medicinal chemists. 
Immediate future work involves screening larger (50,000-compound) libraries, followed by lead development. 
Structure-function correlations enabled by biochemical, cell physiology, and spectroscopic studies in combina-
tion with recent advances in high-resolution RyR cryo-EM25,58,61–66 are expected to resolve the molecular mecha-
nism of action for RyR modulators emerging from reports such as this one.
Methods
Compound handling and preparation of 1536-well assay plates. The LOPAC compounds (Sigma-
Aldrich, MO, USA) were received in 96-well plates and reformatted into assay plates as previously detailed67,68. 
Assay plates were prepared by transferring 5 nL of the 10 mM compound stocks in columns 3–22 and 27–46 or 
DMSO in columns 1–2, 23–26 and 47–48 from the source plates to 1536-well black polypropylene plates using an 
Echo 550 acoustic dispenser. These assay plates were stored at −20 °C prior to usage.
Isolation of SR vesicles. Crude sarcoplasmic reticulum (CSR) vesicles were isolated from porcine longissi-
mus dorsi muscle and porcine cardiac left ventricle tissue by differential centrifugation of homogenized tissue69. 
HSR vesicles, which are enriched in RyR1, were isolated by fractionation of crude skeletal SR vesicles using a 
discontinuous sucrose gradient69. All vesicles were flash-frozen and stored at −80 °C. Immediately prior to the 
fluorescence or [3H]ryanodine binding studies described below, the SR vesicles were stripped of residual endog-
enous CaM by incubation with a peptide derived from the CaM binding domain of myosin light chain kinase, 
followed by sedimentation70.
Expression, purification and labeling of FKBP and CaM. Single-cysteine mutants of FKBP12.6 
(C22A/T85C/C76I) and CaM (T34C) were expressed in Escherichia coli BL21(DE3)pLysS (Agilent Technologies, 
CA, USA), purified and were respectively labeled with fluorescent probes AF488 or AF568 as described previ-
ously51,71. We have previously demonstrated that our system of donor-labeling FKBP12.6 (D-FKBP) with AF488 
and acceptor labeling CaM (A-CaM) with AF568 does neither alter RyR binding nor modulatory activity of these 
proteins71,72.
Preparation of SR vesicles for FRET measurement. Skeletal HSR and cardiac CSR (0.4 mg/ml) mem-
branes were independently pre-incubated with 60 nM D-FKBP, for 90 min, at 37 °C, in a solution containing 
150 mM KCl, 5 mM GSH, 0.1 mg/mL BSA, 1 µg/mL Aprotinin/Leupeptin, 1 mM DTT and 20 mM PIPES (pH 
7.0). To remove unbound D-FKBP, the SR membranes were spun down at 110,000 × g for 20 min, and then resus-
pended to 1 mg/mL (skeletal HSR) and 2 mg/mL (cardiac CSR) in binding buffer consisting of 150 mM KCl, 5 mM 
GSSG, 0.1 mg/mL BSA, 1μg/mL Aprotinin/Leupeptin and 20 mM PIPES, pH 7.0. These samples were then incu-
bated with indicated [A-CaM] for 30 min at 22 °C in binding buffer containing 0.065 mM CaCl2 to give 30 nM free 
Ca2+ in the presence of 1 mM EGTA (calculated by MaxChelator). This labeled SR sample was applied to the assay 
plates in 5 μL aliquots using a Multidrop™ Combi reagent dispenser (Thermo Scientific) with a standard-tube. 
An additional set of the assay plates were loaded with skeletal HSR or cardiac CSR labeled with only D-FKBP (no 
added A-CaM).
Fluorescence data acquisition. FLT measurements were conducted in a top-read FLT-PR designed and 
built by Fluorescence Innovations, Inc33. AF488 donor fluorescence was excited with a 473-nm microchip laser 
from Concepts Research Corporation (Belgium, WI), and emission was acquired with 490-nm long-pass and 
517/20-nm band-pass filters (Semrock, Rochester, NY).
HTS data analysis. FLT waveforms for each well were fit based on a one-exponential decay function using 
least-squares minimization global-analysis software (Fluorescence Innovations, Inc.), as previously described19,33. 
FRET efficiency (E) was determined as the fractional decrease of donor FLT (τD), due to the presence of acceptor 
fluorophore (τDA), using the following equation:
τ
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where σDMSO and σsuramin are the SDs of the control τDA and suramin τDA, respectively; μDMSO and μsuramin are the 
means of the control τDA and suramin τDA, respectively. A compound was considered a Hit if it changed E by 
> 4 SD relative to that of control samples (E0) that were exposed to 0.1% DMSO.
[3H]ryanodine binding to SR vesicles. In 96-well plates, HSR vesicles (1 mg/ml) and cardiac CSR vesicles 
(3 mg/mL) were pre-incubated with 0.02% DMSO or Hit compound, with or without 300 nM CaM, for 30 min at 
22 °C in a solution containing 150 mM KCl, 5 mM GSSG, 1 µg/mL Aprotinin/Leupeptin, 1 mM EGTA, and 65 µM 
or 1.02 mM CaCl2 (as determined by MaxChelator to yield 30 nM or 30 μM of free Ca2+, respectively), 0.1 mg/
mL BSA and 20 mM K-PIPES (pH 7.0). Non-specific and maximal [3H]ryanodine binding to SR were separately 
assessed by addition of 40 µM non-radioactively labeled ryanodine or 5 mM Adenylyl-imidodiphosphate, respec-
tively. Such control samples were each distributed over 4 wells/plate. Binding of [3H]ryanodine (10 and 15 nM for 
cardiac and skeletal SR, respectively) was determined after a 3-h incubation (37 °C) and filtration through grade 
GF/B Glass Microfiber filters (Brandel Inc., Gaithersburg, MD, US) using a Brandel Harvester. In 4 mL of Ecolite 
Scintillation cocktail (MP biomedicals, Solon, OH, USA), [3H] on filter was counted using a Beckman LS6000 
scintillation counter (Fullerton, CA).
Muscle preparation for single-fiber imaging. All experiments were approved by The University of 
Queensland (UQ) Human Ethics Committee, and were performed in accordance with the relevant guidelines and 
regulations. Subjects signed informed consent forms prior to be their involvement in this study. Human muscle 
biopsies were collected under local anesthesia from the vastus lateralis (VL) muscle, as previously described73. 
All subjects who volunteered in this study were fit and in good physical condition at the time of biopsy. Muscle 
biopsies were collected under local anesthesia (Xylocaine, 10 mg ml−1 with adrenaline, 5 µg ml−1) from the 
mid-portion of VL, using a 6 mm Bergstrom biopsy needle modified for manual suction74. Muscle tissue collected 
from the biopsy needle was blotted on filter paper (Whatman No 1) to remove blood and external fluid. Muscle 
tissue was pinned to Sylgard set in a petri dish containing paraffin oil.
All experimental methods using rats were approved by The Animal Ethics Committee at The University of 
Queensland. Five month old Wistar rats (UQ Biological Resources, Brisbane) were euthanized by asphyxiation 
via CO2 exposure, and the extensor digitorum longus (EDL) were rapidly excised.
Bundles of fibers were isolated and exposed to a physiological solution containing 145 mM NaCl, 3 mM 
KCl, 2.5 mM CaCl2, 2 mM MgCl2, 2.5 mM rhod-5N salt, 0.05 mM BTS (Calbiochem) and 10 mM HEPES (pH 
7.4). Bundles were allowed 15 min to equilibrate with the physiological solution and then individual fibers were 
isolated and mechanically skinned. Skinned fibers with fluorescent dye trapped in the t-system were mounted 
on a custom-made chamber that used a coverslip as a base and bathed in a standard internal solution, which 
contained 50 mM EGTA, 90 mM HEPES, 126 mM K+, 36 mM Na+, 8 mM ATP, 1 mM Mg2+, 10 mM creatine 
phosphate and 200 nM Ca2+. For each experimental model, SR and t-system Ca2+ was released with 30 mM 
caffeine in an internal solution with 0.01 mM Mg2+. RyR modulators myricetin, chloroxine (HTS ‘Hits’) and 
tetracaine (known RyR inhibitor) were dissolved as stock solutions in DMSO and added to internal solutions 
(< 0.1% DMSO).
Confocal imaging for RyR1 leak in skeletal muscle fibers. Mounted skinned fibers were imaged using 
an Olympus FV1000 confocal microscope equipped with an Olympus 0.9NA 40x Plan-Apochromat objective. 
Rhod-5N was excited with 543-nm HeNe laser and the emission was filtered using the Olympus spectra detector. 
For tracking Ca2+ movements across the t-system membrane, images were continuously recorded in xyt mode 
with an aspect ratio of 256 × 512, with the long aspect of the image parallel with that of the preparation. Temporal 
resolution of imaging in this mode where the fluorescence signal was within the borders of the fiber was 0.8 s.
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[Ca2+]t-sys = concentration of ionized calcium concentration in the t-system, (t) = point in time, Kd = dissociation 
constant of the dye/Ca2+ complex, F = fluorescence intensity (arbitrary units) taken at the point of plateau after a 
solution is applied, Fmax = maximum fluorescence, Fmin = minimum fluorescence. The Kd,(Ca2+) of rhod-5N was 
determined previously75 as 0.8 mM.
To determine the effect of RyR modulators on the RyR Ca2+ leak, isolated mechanically skinned fibers were 
continuously imaged as described above, to obtain a record of t-system rhod-5N fluorescence changes over time 
as the cytoplasmic solution bathing the fiber was changed. SR and t-system Ca2+ was released by bathing the 
fiber in a solution where free [Mg2+] was lowered from 1 to 0.01 mM in the presence of 30 mM caffeine (“release 
solution”). This chronically opened the RyR, thus thoroughly depleting the SR of Ca2+ and consequent depletion 
of t-system Ca2+ occurred via the activation of SOCE. Alternatively, the application of 200 nM [Ca2+]cyto standard 
internal solution allowed the uptake of Ca2+ and the [Ca2+]t-sys reached a steady-state that was partially depend-
ent on Ca2+ leaking through RyRs into the tight junctional space between the t-system and SR membranes31. By 
blocking the RyR with tetracaine (1 mM), it was possible to separate the influence of RyR Ca2+ leak on t-system 
Ca2+ steady-state from the level determined by the lower concentration of bulk cytoplasmic Ca2+ that could 
otherwise enter the junctional space. This difference provides a measure of RyR Ca2+ leak, or a reference for Ca2+ 
leak that we can use to assess the effectiveness of novel RyR modulators in a human muscle fiber. Myricetin (0.1, 1 
and 10 μM), chloroxine (1, 10 and 100 μM) or DMSO control (0.1%) were added to the standard internal solution 
bathing the skinned fibers, at known concentrations, to assess their influence on RyR Ca2+ leak.
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Electrically evoked Ca2+ transients in rat skeletal muscle fibers. Skinned rat fibers were prepared 
and bathed in a resting physiological solution containing 100 nM Ca2+, 1 mM Mg2+, 36 mM Na+, 126 mM K+, 
1 mM EGTA, 90 mM HEPES, 5 mM rhod-2, 10 mM creatine phosphate and 8 mM ATP (pH 7.4). The Ca2+ sensi-
tive dye rhod-2 was used to track cytosolic Ca2+ transients when exposed to electrical stimulation. Field pulses at 
1 Hz frequency and 4 ms in duration were applied across platinum electrodes parallel to the long axis of the fiber 
as previously described54,76. Imaging for electrical stimulation experiments was in xt mode, at a rate of 2 ms·line−1. 
Myricetin (0.1, 1 and 10 μM), chloroxine (1, 10 and 100 μM) or DMSO control (0.1%) were added to the physio-
logical solution. Electrical stimulation recordings were taken no more than 1 min post application of modulator.
Analysis and presentation of data. We report data as means ± SEM. To determine statistical difference, 
we used 2-sided Student’s unpaired T-test or one-way ANOVA followed by Tukey’s post-hoc test, as indicated. 
We used GraphPad Prism and OriginLab Origin software packages to perform these statistical analyses were 
performed with. Significance was accepted at P < 0.05. IC50 values were derived from dose-response fits to the 
Hill function.
Data availability
The authors declare that all data supporting the findings of this study are available within the article and its 
supplementary information file.
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